Abivax (NASDAQ: ABVX) shares surged over 1,740% last year due to progress with obefazimod. The drug is being developed to treat ulcerative colitis, providing symptom relief without weakening the immune system. Clinical trials showed promising results, and a potential acquisition by Eli Lilly could further boost Abivax’s value by 72%.

Obefazimod offers a new approach to treating ulcerative colitis, targeting a wider patient population with fewer side effects than current therapies. Eli Lilly’s potential acquisition bid, offering a 72% premium, underscores the drug’s potential market impact. While risks remain, Abivax’s innovative treatment could revolutionize the UC market and attract major pharmaceutical interest.

Investors eyeing Abivax should consider obefazimod’s strong clinical trial results and potential acquisition prospects. While regulatory setbacks could impact the stock, Eli Lilly’s interest signals confidence in the drug’s future success. With the healthcare market expanding, Abivax’s innovative approach to treating UC could lead to substantial growth, making it a risky but potentially rewarding investment opportunity.

Read more at Yahoo Finance: This Healthcare Stock Could Soar by 72% in 2026